The effects of group mentalization-based treatment-P on cognitive emotion regulation and tic symptoms in children with tic disorders.

Psychol PsychotherApr 29, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Yuhu Guo, Rasoul Heshmati, Maedeh Heidary et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the impact of mentalization-based treatment-P on cognitive emotion regulation and tic symptoms in children with tic disorders. Conducted with 30 children in Mako, Iran, the study found significant improvements in cognitive emotion regulation and reductions in tic severity, with p-values less than 0.001 for both outcomes.

Key findings

  • Mentalization-based group therapy significantly improved cognitive emotion regulation (p < .001).
  • The intervention led to a significant reduction in overall tic severity scores (p < .001).

Why it matters

Improving cognitive emotion regulation and reducing tic symptoms can enhance the quality of life for children with tic disorders. Effective interventions like mentalization-based therapy may provide valuable therapeutic options in clinical practice.

Source

PubMed · PMID 42053213Free full text on PubMed Central

Published in Psychol Psychother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.